Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors

被引:35
作者
Zeng, PY
Rane, N
Du, W
Chintapalli, J
Prendergast, GC
机构
[1] Lankenau Inst Med Res, Wynnewood, PA 19096 USA
[2] DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA USA
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[4] Thomas Jefferson Univ, Jefferson Med Sch, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
关键词
Ras; Rac; Rho; actin;
D O I
10.1038/sj.onc.1206181
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent genetic investigations have established that RhoB gain-of-function is sufficient to mediate the antitransforming effects of farnesyltransferase inhibitors (FTIs) in H-Ras-transformed fibroblast systems. In this study, we addressed the breadth and mechanism of RhoB action in epithelial cells transformed by oncoproteins which are themselves insensitive to FTI inactivation. Rat intestinal epithelial (RIE) cells transformed by activated K-Ras or Rac1 were highly sensitive to FTI-induced actin reorganization and growth inhibition, despite the inability of FTI to block prenylation of either K-Ras or Rac1. Ectopic expression of the geranylgeranylated RhoB isoform elicited in cells by FTI treatment phenocopied these effects. Analysis of RhoB effector domain mutants pointed to a role for PRK, a Rho effector kinase implicated in the physiological function of RhoB in intracellular receptor trafficking, and these findings were supported further by experiments in a fibroblast system. We propose that FTIs recruit the antioncogenic RhoB protein in the guise of RhoB-GG to interfere with signaling by pro-oncogenic Rho proteins, possibly by sequestering common exchange factors or effectors such as PRK that are important for cell transformation.
引用
收藏
页码:1124 / 1134
页数:11
相关论文
共 47 条
[1]   INTRACELLULAR-LOCALIZATION OF THE P21(RHO) PROTEINS [J].
ADAMSON, P ;
PATERSON, HF ;
HALL, A .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :617-627
[2]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[3]   PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 [J].
Balendran, A ;
Casamayor, A ;
Deak, M ;
Paterson, A ;
Gaffney, P ;
Currie, R ;
Downes, CP ;
Alessi, DR .
CURRENT BIOLOGY, 1999, 9 (08) :393-404
[4]   Farnesyltransferase inhibitors - Potential role in the treatment of cancer [J].
Cox, AD .
DRUGS, 2001, 61 (06) :723-732
[5]   Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis - Identification by a novel, small pool expression cloning strategy [J].
Cryns, VL ;
Byun, Y ;
Rana, A ;
Mellor, H ;
Lustig, KD ;
Ghanem, L ;
Parker, PJ ;
Kirschner, MW ;
Yuan, JY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) :29449-29453
[6]  
Du W, 1999, CANCER RES, V59, P2059
[7]  
Du W, 1999, MOL CELL BIOL, V19, P1831
[8]  
Du W, 1999, CANCER RES, V59, P4208
[9]  
DU W, 1999, CANCER RES, V59, P5924
[10]   Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase [J].
Flynn, P ;
Mellor, H ;
Casamassima, A ;
Parker, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (15) :11064-11070